Indication
Genitourinary cancer
2 clinical trials
2 products
Clinical trial
An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AB-1015Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)Status: Recruiting, Estimated PCD: 2026-10-01
Product
STAR0602